Emerging Issues Regarding the Effects of the Microbiome on Lung Cancer Immunotherapy

TL;DR

This paper explores how the microbiome influences lung cancer immunotherapy and how manipulating it could improve treatment outcomes.

Contribution

The paper highlights the role of specific bacterial populations in immunotherapy response and emphasizes the need to study microbiome modulation strategies.

Findings

Specific bacterial populations are linked to better immunotherapy outcomes in lung cancer patients.

Modulating the microbiome through methods like fecal transplants or probiotics is being tested to enhance treatment effectiveness.

Understanding microbiome-immune interactions could help mitigate adverse events in immunotherapy.

Abstract

Lung cancer remains the deadliest malignancy, with limited effective and long-term therapeutic options. Immunotherapy has revolutionized the therapeutic landscape of lung cancer. However, not everyone with lung cancer responds to immunotherapy, while, inpatients who temporarily derive clinical benefit, resistance eventually develops. The host microbiome has emerged as a pivotal player in cancer growth and progression. It has been implicated in the intricate connections between immune cells and tumor cells, ultimately augmenting immunotherapy efficacy in solid tumors, while simultaneously mitigating the immune-related adverse events associated with this type of treatment. Notably, lung cancer patients who obtain benefit from immunotherapy have been found to be colonized with specific bacterial populations, and it is this observation that the scientific community is trying to exploit, aspiring to improve lung cancer immunotherapy response rates. Delving deeper into the molecular mechanisms underpinning the effects of the microbiome on immunotherapy is an area that we should pay attention to if we want to utilize microbiome modulation in everyday clinical practice. Fecal microbiota transplantation, probiotics, targeted antibiotic interventions, and dietary modifications are among the strategies that are under investigation in clinical trials, with the ultimate endpoint of lengthening the life expectancy of lung cancer patients.

Figures